TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.
52 Week Range
TapImmune is developing immunotherapies for a variety of cancers that are designed to target both tumors and metastatic disease. The company’s next-generation technology is designed to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells.
IR CONTACT DETAILS
50 N. Laura St. Suite 2500
Jacksonville, FL 32202